Kyntra Bio and Qilu Pharmaceutical side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Kyntra Bio | Qilu Pharmaceutical |
|---|---|---|
| Phase 1 | 00% | Qilu Pharmaceutical: 24 of its 72 programs at phase 1
and 19 more — sign in to see them all |
| Phase 2 | Kyntra Bio: 1 of its 2 programs at phase 2 | Qilu Pharmaceutical: 14 of its 72 programs at phase 2
and 9 more — sign in to see them all |
| Phase 3 | 00% | Qilu Pharmaceutical: 32 of its 72 programs at phase 3
and 27 more — sign in to see them all |
| Approved, new studies | Kyntra Bio: 1 of its 2 programs at approved, new studies
| Qilu Pharmaceutical: 2 of its 72 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyntra Bio0 readouts · 0 phase 3 | · | · | · | · | · | · | · | · | · | · | · | · |
| Qilu Pharmaceutical37 readouts · 13 phase 3 | Qilu Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion
| Qilu Pharmaceutical, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3
and 4 more — sign in to see them all | Qilu Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Qilu Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion
| Qilu Pharmaceutical, Mar ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Qilu Pharmaceutical, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3
| Qilu Pharmaceutical, May ’27: 4 programs whose next study reaches primary completion, 4 in phase 3
| Qilu Pharmaceutical, Jun ’27: 7 programs whose next study reaches primary completion, 1 in phase 3
and 2 more — sign in to see them all | Qilu Pharmaceutical, Jul ’27: 1 program whose next study reaches primary completion
| Qilu Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion
| · | Qilu Pharmaceutical, Oct ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
|
Changed in the last 90 days
Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Kyntra Bio
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Qilu Pharmaceutical
New programs 7
- QLS7402 Injectionphase 1 · first study · Nov 10 · Obesity
- QLS2406-1 injectionphase 1 · first study · Nov 9 · Obesity
- QLS5314phase 1 · first study · Oct 30
- QLS2416phase 1 · first study · Oct 23 · Lupus Erythematosus, Systemic
- QLS2312phase 1 · first study · Sep 30
- QLS2401phase 1 · first study · Sep 30 · Prostatic Neoplasms
Qilu Pharmaceutical: new programs in 90 days
- QLS7402 Injectionphase 1 · first study · Nov 10
- QLS2406-1 injectionphase 1 · first study · Nov 9
- QLS5314phase 1 · first study · Oct 30
- QLS2416phase 1 · first study · Oct 23
- QLS2312phase 1 · first study · Sep 30
and 2 more — sign in to see them all
Reached a new phase 2
Study stopped 0
None
Primary completion later 1
- 3-6mg QLM1016phase 3 · Jul 2026 → Oct 2026 (+3 mo) · moved Oct 14 · NCT06799559
Where they overlap
Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.
| Condition | Kyntra Bio | Qilu Pharmaceutical |
|---|---|---|
| Prostatic Neoplasmsboth · compare here | Kyntra Bio in Prostatic Neoplasms: 1 program Their studies: Kyntra Bio’s studies of Prostatic Neoplasms in search | |
| Multiple Myelomaboth · compare here | Kyntra Bio in Multiple Myeloma: 1 program Their studies: Kyntra Bio’s studies of Multiple Myeloma in search | Qilu Pharmaceutical in Multiple Myeloma: 4 programs Their studies: Qilu Pharmaceutical’s studies of Multiple Myeloma in search |
| Anemiaboth · compare here | Kyntra Bio in Anemia: 1 program
Their studies: Kyntra Bio’s studies of Anemia in search | Qilu Pharmaceutical in Anemia: 1 program
Their studies: Qilu Pharmaceutical’s studies of Anemia in search |
| Myelodysplastic Syndromesboth · compare here | Kyntra Bio in Myelodysplastic Syndromes: 1 program
Their studies: Kyntra Bio’s studies of Myelodysplastic Syndromes in search | Qilu Pharmaceutical in Myelodysplastic Syndromes: 1 program
Their studies: Qilu Pharmaceutical’s studies of Myelodysplastic Syndromes in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Kyntra Bio | Qilu Pharmaceutical |
|---|---|---|
| EGLN1 | roxadustatrule | daprodustatrule |
| EGLN2 | roxadustatrule | daprodustatrule |
| EGLN3 | roxadustatrule | daprodustatrule |
| P4HTM | roxadustatrule | daprodustatrule |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.